查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1579064

葡萄膜炎治療藥物市場：按治療類型、疾病類型、原因、分銷管道 - 全球預測 2025-2030

Uveitis Treatment Market by Treatment Type (Analgesics, Antibiotics, Antifungal), Disease Type (Anterior Uveitis, Intermediate Uveitis, Panuveitis), Cause, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年葡萄膜炎治療藥物市值為7.2465億美元，預計到2024年將達到7.8324億美元，複合年成長率為8.48%，到2030年將達到12.8123億美元。

葡萄膜炎藥物是指旨在控制葡萄膜炎的治療策略。葡萄膜炎是眼睛葡萄膜的發炎，如果不治療可能導致視力喪失。此類治療包括皮質類固醇、免疫抑制劑、生物製藥和手術介入。這些治療對於保護視力、緩解疼痛和解決感染疾病或自體免疫疾病等根本原因至關重要。主要應用包括前、中、後和全葡萄膜炎管理，最終用戶是醫院、眼科診所和專業眼科護理中心。

主要市場統計
基準年[2023] 7.2465億美元
預測年份 [2024] 7.8324 億美元
預測年份 [2030] 1,281.23 百萬美元
複合年成長率（%） 8.48%

由於人們認知的提高、生物製藥開發的進步以及全球自體免疫疾病盛行率的上升，葡萄膜炎治療市場正在不斷成長。診斷方法的改進和對病理學的更深入了解正在進一步支持市場擴張。生物目標和新型藥物輸送系統的開發存在重大商機，例如有望提高療效和患者依從性的緩釋性眼部植入。鼓勵公司投資研發，專注於個人化醫療方法，並利用夥伴關係關係進行創新技術整合。

然而，不斷上漲的治療成本、潛在的藥物副作用以及低收入地區缺乏藥物供應給市場成長帶來了挑戰。此外，監管障礙和新治療方法的緩慢採用也構成了重大挑戰。解決這些限制因素需要增加對負擔得起的治療的投資，並透過策略夥伴關係和政府支持擴大可及性。

新的研究領域包括基因治療和生活方式改善干涉措施，預計將提供新的治療途徑。在不斷創新和新進入者的推動下，市場本質上是充滿活力和競爭的。旨在實現成長的公司應專注於透過資料分析對患者行為進行競爭考察洞察，並保持以患者為中心的方法來識別未滿足的需求並獲得競爭優勢。

市場動態：快速發展的葡萄膜炎治療市場的關鍵市場洞察

葡萄膜炎藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 人口老化加劇和慢性眼部疾病盛行率增加
    • 葡萄膜炎影像診斷技術進展
    • 藥物傳輸方法的技術改進
  • 市場限制因素
    • 治療時間長、治療費用大
  • 市場機會
    • 持續研究和開發創新治療方法
    • 遠端醫療和遠距患者監護的出現
  • 市場挑戰
    • 與使用全身免疫抑制劑相關的副作用

波特的五力：駕馭葡萄膜炎藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解葡萄膜炎治療藥物市場的外部影響

外部宏觀環境因素在影響葡萄膜炎治療藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解葡萄膜炎治療藥物市場的競爭狀況

對葡萄膜炎治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣葡萄膜炎治療市場供應商的績效評估

FPNV 定位矩陣是評估葡萄膜炎治療藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪葡萄膜炎治療藥物市場的成功之路

對於想要加強在全球市場的影響力的公司來說，葡萄膜炎治療藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人口老化加劇和慢性眼科疾病增加
      • 葡萄膜炎影像診斷技術進展
      • 藥物傳輸方法的技術改進
    • 抑制因素
      • 治療時間長、治療費用大
    • 機會
      • 持續研究並開發創新治療方法
      • 遠端醫療和遠距患者監護的出現
    • 任務
      • 與使用全身免疫抑制劑相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章葡萄膜炎治療藥物市場（依治療類型）

  • 止痛藥
  • 抗生素
  • 抗真菌劑
  • 抗病毒藥物
  • 皮質類固醇
  • 睫狀肌麻痺藥
  • 免疫抑制劑
  • 單株抗體

第7章葡萄膜炎治療藥物市場：依疾病類型

  • 前葡萄膜炎
  • 中間葡萄膜炎
  • 葡萄膜炎
  • 後葡萄膜炎

第8章葡萄膜炎治療藥物市場（按原因）

  • 傳染性的
  • 非傳染性的

第9章葡萄膜炎治療藥物市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章 北美和南美葡萄膜炎治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區葡萄膜炎治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲葡萄膜炎治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Accutome, Inc.
  • Ajanta Pharma Ltd.
  • Alcon Vision LLC
  • Allergan PLC
  • Amorphex Therapeutics Holdings, Inc.
  • Appasamy Ocular Device Pvt Ltd.
  • Astellas Pharma Inc.
  • Bausch & Lomb Incorporated
  • Bayer AG
  • Cipla Ltd.
  • Entod Pharmaceuticals Ltd.
  • EyePoint Pharmaceuticals, Inc.
  • Fera Pharmaceuticals
  • His Eyeness Ophthalmics Pvt Ltd.
  • Intas Pharmaceuticals Ltd.
  • JB Chemicals And Pharmaceuticals Ltd.
  • Kubota Vision Inc.
  • Merck & Co. Inc.
  • Micro Labs Ltd.
  • Nidek Co Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Sunways India Pvt Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-742BD5184C9B

The Uveitis Treatment Market was valued at USD 724.65 million in 2023, expected to reach USD 783.24 million in 2024, and is projected to grow at a CAGR of 8.48%, to USD 1,281.23 million by 2030.

Uveitis treatment refers to therapeutic strategies aimed at managing uveitis, an inflammation of the uvea in the eye that can result in vision loss if untreated. The scope of such treatments encompasses corticosteroids, immunosuppressants, biologics, and surgical interventions. These treatments are crucial for preserving vision, alleviating pain, and addressing underlying causes such as infection or autoimmune diseases. Major applications include management of anterior, intermediate, posterior, and panuveitis, with end-users being hospitals, ophthalmic clinics, and specialty eye care centers.

KEY MARKET STATISTICS
Base Year [2023] USD 724.65 million
Estimated Year [2024] USD 783.24 million
Forecast Year [2030] USD 1,281.23 million
CAGR (%) 8.48%

The uveitis treatment market is experiencing growth due to increasing awareness, advancements in biologic drug development, and a rising prevalence of autoimmune disorders worldwide. Improved diagnostics and a better understanding of pathophysiological aspects are further driving market expansion. Significant opportunities lie in the development of targeted biologics and novel drug delivery systems, such as sustained-release ocular implants, which promise enhanced efficacy and patient compliance. Companies are advised to invest in R&D, focusing on personalized medicine approaches and leveraging partnerships for innovative technology integration.

However, market growth is challenged by the high cost of treatment, potential side effects of drugs, and a lack of availability in low-income regions. Additionally, regulatory hurdles and the slow adoption of novel therapies pose significant challenges. Addressing these limitations involves increasing investment in affordable therapies and expanding access through strategic collaborations and governmental support.

Emerging research areas include the investigation of gene therapy and lifestyle modification interventions, which show promise in offering new pathways for treatment. The market is inherently dynamic and competitive, driven by ongoing innovation and the entry of new market players. Companies poised for growth should focus on harnessing data analytics for patient behavioral insights and maintain a patient-centric approach in their strategies to tap into unmet needs and gain a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Uveitis Treatment Market

The Uveitis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising aging population and increasing prevalence of chronic eye disorders
    • Advancement in diagnostic techniques for imaging uveitis
    • Technical improvement in drug delivery methods
  • Market Restraints
    • Long-term treatment and huge treatment costs
  • Market Opportunities
    • Ongoing research and development for innovative treatment therapies
    • Emergence of telemedicine and remote monitoring of patients
  • Market Challenges
    • Side-effects associated with the usage of systemic immunosuppressive medications

Porter's Five Forces: A Strategic Tool for Navigating the Uveitis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Uveitis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Uveitis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Uveitis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Uveitis Treatment Market

A detailed market share analysis in the Uveitis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Uveitis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Uveitis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Uveitis Treatment Market

A strategic analysis of the Uveitis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Uveitis Treatment Market, highlighting leading vendors and their innovative profiles. These include Accutome, Inc., Ajanta Pharma Ltd., Alcon Vision LLC, Allergan PLC, Amorphex Therapeutics Holdings, Inc., Appasamy Ocular Device Pvt Ltd., Astellas Pharma Inc., Bausch & Lomb Incorporated, Bayer AG, Cipla Ltd., Entod Pharmaceuticals Ltd., EyePoint Pharmaceuticals, Inc., Fera Pharmaceuticals, His Eyeness Ophthalmics Pvt Ltd., Intas Pharmaceuticals Ltd., J B Chemicals And Pharmaceuticals Ltd., Kubota Vision Inc., Merck & Co. Inc., Micro Labs Ltd., Nidek Co Ltd., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Sunways India Pvt Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Uveitis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Analgesics, Antibiotics, Antifungal, Antivirals, Corticosteroids, Cycloplegic Agents, Immunosuppressant, and Monoclonal Antibodies.
  • Based on Disease Type, market is studied across Anterior Uveitis, Intermediate Uveitis, Panuveitis, and Posterior Uveitis.
  • Based on Cause, market is studied across Infectious and Noninfectious.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising aging population and increasing prevalence of chronic eye disorders
      • 5.1.1.2. Advancement in diagnostic techniques for imaging uveitis
      • 5.1.1.3. Technical improvement in drug delivery methods
    • 5.1.2. Restraints
      • 5.1.2.1. Long-term treatment and huge treatment costs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development for innovative treatment therapies
      • 5.1.3.2. Emergence of telemedicine and remote monitoring of patients
    • 5.1.4. Challenges
      • 5.1.4.1. Side-effects associated with the usage of systemic immunosuppressive medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Uveitis Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Analgesics
  • 6.3. Antibiotics
  • 6.4. Antifungal
  • 6.5. Antivirals
  • 6.6. Corticosteroids
  • 6.7. Cycloplegic Agents
  • 6.8. Immunosuppressant
  • 6.9. Monoclonal Antibodies

7. Uveitis Treatment Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Anterior Uveitis
  • 7.3. Intermediate Uveitis
  • 7.4. Panuveitis
  • 7.5. Posterior Uveitis

8. Uveitis Treatment Market, by Cause

  • 8.1. Introduction
  • 8.2. Infectious
  • 8.3. Noninfectious

9. Uveitis Treatment Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Uveitis Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Uveitis Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Uveitis Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Accutome, Inc.
  • 2. Ajanta Pharma Ltd.
  • 3. Alcon Vision LLC
  • 4. Allergan PLC
  • 5. Amorphex Therapeutics Holdings, Inc.
  • 6. Appasamy Ocular Device Pvt Ltd.
  • 7. Astellas Pharma Inc.
  • 8. Bausch & Lomb Incorporated
  • 9. Bayer AG
  • 10. Cipla Ltd.
  • 11. Entod Pharmaceuticals Ltd.
  • 12. EyePoint Pharmaceuticals, Inc.
  • 13. Fera Pharmaceuticals
  • 14. His Eyeness Ophthalmics Pvt Ltd.
  • 15. Intas Pharmaceuticals Ltd.
  • 16. J B Chemicals And Pharmaceuticals Ltd.
  • 17. Kubota Vision Inc.
  • 18. Merck & Co. Inc.
  • 19. Micro Labs Ltd.
  • 20. Nidek Co Ltd.
  • 21. Novartis AG
  • 22. Pfizer Inc.
  • 23. Sun Pharmaceutical Industries Ltd.
  • 24. Sunways India Pvt Ltd.
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. UVEITIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. UVEITIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL UVEITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES UVEITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES UVEITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UVEITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. UVEITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. UVEITIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL UVEITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. UVEITIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY ANTIFUNGAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY CYCLOPLEGIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY ANTERIOR UVEITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY INTERMEDIATE UVEITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY PANUVEITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY POSTERIOR UVEITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY INFECTIOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY NONINFECTIOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES UVEITIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. UVEITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. UVEITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023